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A commentary on
Depletion of the Fragile X Mental Retardation Protein in Embryonic Stem Cells Alters the
Kinetics of Neurogenesis
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Cells 35, 374–385. doi: 10.1002/stem.2505
Fragile X syndrome (FXS) is a neurodevelopmental disorder characterized by cognitive
impairment, attention deficit, hyperactivity, anxiety, unstable mood, autistic behaviors, language
delay, and seizures (Hagerman et al., 2010). This X-linked chromosome disorder is the most
common known cause of autism with 30% of boys meeting full autism criteria (Harris et al., 2008).
In the majority of cases, FXS is caused by a trinucleotide repeat expansion (CGG) in the FMR1
gene, which causes loss of expression of fragile Xmental retardation protein (FMRP) (Santoro et al.,
2011). FMRP is an RNA binding protein that plays a critical role in synaptic protein synthesis. There
are medications for managing symptoms of FXS, but there are no disease specific therapies and no
cure.
The main challenges confronting the FXS field include early diagnosis, validating outcome
measures for clinical trials, and identifying viable treatment targets. In terms of early diagnosis,
population wide screening is feasible. Recent advances in FMR1 allele analysis allow rapid and
inexpensive assessment of CGG repeat size, the number of AGG interruptions, and methylation
status from blood or saliva samples (Hayward et al., 2016). However, a FXS genetic test is not
included in the newborn screening (NBS) panel in theUnited States due to ethical debates regarding
screening for genetic disorders where no therapeutic intervention exists and contemporaneous
identification of premutation carriers. Proponents of FXS NBS argue that screening is needed for
early detection and intervention (Tassone, 2014). Numerous disease mechanism-based drugs are
in clinical trials for FXS and early intervention may be required for better therapeutic efficacy.
Preliminary results indicate that babies with FMR1 premutations exhibit an altered developmental
trajectory on measures of nonverbal communication and hyperresponsivity to sensory experiences
(Wheeler et al., 2016). Thus, early diagnosis could benefit both full and premutation carriers.
With regard to the urgent need to validate outcome measures for FXS clinical trials, recent trials
failed on primary endpoints (Berry-Kravis et al., 2013, 2016). Soluble amyloid precursor protein
alpha (sAPPα) is elevated in plasma of autistic children and can be detected in human umbilical
cord blood supporting feasibility of this APP metabolite as an early diagnostic autism biomarker
(Sokol et al., 2006; Bailey et al., 2008). APP metabolites are also altered in FXS (Westmark et al.,
2016), and a recent trial with acamprosate indicates that sAPPα is responsive to drug treatment
(Erickson et al., 2014).
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FIGURE 1 | The APP Theory of FXS. FXS is a debilitating genetic disorder with no cure and few therapeutic options. Excessive signaling through mGluR5 leads to
the increased translation of numerous synaptic proteins and exaggerated long-term depression (LTD) in Fmr1KO mice (Huber et al., 2002; Bear et al., 2004). Two of
the overexpressed proteins are APP and its metabolite amyloid-beta (Westmark and Malter, 2007), which have been well-studied in Alzheimer’s disease (AD).
Accumulating evidence suggests that dysregulated levels of APP and its catabolites contribute to FXS pathology. Multiple recent FXS clinical trials have failed on their
primary endpoints indicating that there is a compelling need for validated biomarkers and outcome measures in the field. We hypothesize that APP and its metabolites
may be viable blood-based biomarkers that are responsive to drug treatment in FXS, and that pharmaceuticals under study for the modulation of APP and
amyloid-beta in AD may be viable therapeutic candidates for FXS. In mice, FMRP binds to a guanine-rich region in the coding region of App mRNA and regulates
protein translation through mGluR5 signaling (Westmark and Malter, 2007). APP and amyloid-beta levels are elevated in Fmr1
KO brain (Westmark and Malter, 2007;
Liao et al., 2008; Pasciuto et al., 2015); and behavior, dendritic spine, electrophysiology, and seizure phenotypes are rescued after genetic or pharmaceutical
modulation of APP levels in Fmr1KO mice (Westmark et al., 2011; Pasciuto et al., 2015). These data prompted studies in human samples to determine if APP
metabolites may be viable biomarkers for drug efficacy in FXS. In humans, there are altered levels of APP metabolites in FXS blood plasma, lymphoblastoid cells, and
brain (Westmark et al., 2011; Pasciuto et al., 2015; Ray et al., 2016); and sAPPα levels are responsive to drug treatment in FXS children (Erickson et al., 2014). FXS is
a family of disorders where older premutation carriers can develop fragile X tremor-ataxia syndrome (FXTAS). Elderly FXTAS subjects have elevated APP mRNA in
blood and APP and amyloid plaques in brain; aged FXTAS knockin mice exhibit elevated brain APP (Tassone et al., 2012; Mateu-Huertas et al., 2014; Renoux et al.,
2014). Findings from the mouse and human studies prompted cell culture experiments. In human neuroblastoma cells, there is dual regulation of APP mRNA
translation by the RNA binding proteins hnRNP C and FMRP, which compete for binding the guanine-rich regulatory element in the coding region of the message (Lee
et al., 2010). There is increased expression of APP in Fmr1KO mouse cortical neurons and mESC; and genetic, lentiviral or pharmaceutical modulation of APP rescues
spine morphology and accelerated neurogenesis (Westmark and Malter, 2007; Westmark et al., 2011; Pasciuto et al., 2015; Khalfallah et al., 2017). FMRP depletion
in mESC leads to increased expression of APP and Ascl1, which leads to accelerated neuronal differentiation (Khalfallah et al., 2017). Ascl1 is a transcription factor,
and of interest, amyloid-beta is a putative transcription factor for APP and BACE1 (Maloney and Lahiri, 2011) and upregulates Ascl1 expression (Uchida et al., 2007).
Thus, enhanced transcriptional and translational events mediated by Ascl1, APP and amyloid-beta in the absence of FMRP could drive accelerated neurogenesis in
FXS. The FXS mESC model developed by the Bardoni laboratory could be utilized to study cell signaling events at the earliest stage of FXS pathology, including APP
synthesis and processing, and be developed into a high throughput assay for drug testing including secretase modulators. Bench-to-bedside plans would need to
include validation of identified targets and drugs in future animal and human studies. Overall, this novel mESC model offers a timely tool to study the early events of
FXS pathogenesis including the expression and processing of APP.
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Concerning identification of viable treatment targets,
excessive signaling through metabotropic glutamate receptor 5
(mGluR5) leads to increased translation of numerous synaptic
proteins and altered plasticity in FXS (Bear et al., 2004). Many
of these proteins are under investigation as potential FXS
drug targets. Of relevance herein, two overexpressed proteins
are APP and amyloid-beta (Westmark and Malter, 2007),
which have been well-studied in Alzheimer’s disease (AD).
Accumulating evidence suggests that dysregulated levels of APP
metabolites contribute to FXS pathology (Figure 1), supporting
the hypothesis that pharmaceuticals under study for modulation
of APP and amyloid-beta in AD may be viable therapeutic
strategies for FXS (Westmark et al., 2013; Pasciuto et al., 2015).
In their Stem Cells article, Khalfallah and colleagues report
the development of a mouse embryonic stem cell (mESC)-based
FXS disease model. Specifically, they generated an isogenic stable
cell line by targeted knockdown of the Fmr1 gene with a short
hairpin (sh)RNA, and used this model to demonstrate that
decreased expression of FMRP triggers accelerated differentiation
of neurons and elevated expression of the transcription factor
Ascl1/Mash1 and the membrane glycoprotein APP (Khalfallah
et al., 2017). Fmr1 mRNA and protein levels were specifically
and significantly reduced in shFmr1 mESC compared to control
cells while expression of FMRP homologs was unaffected. Fmr1
knockdown did not alter mESC morphology or proliferation;
however, there was premature generation of neural progenitors
as evidenced by a rosette-like morphology at 4 days in vitro
and altered expression of neuro-specific markers. The authors
confirmed that neurogenesis was accelerated in vivo in Fmr1KO
mouse embryonic brain. They further showed that accelerated
neurogenesis in the shFmr1mESC model was rescued by genetic
introduction of the human FMR1 gene or pharmacological
treatment with BACE-1 inhibitor LY2811376.
Neurogenesis is the process through which neurons are
generated from neural stem and progenitor cells. Both FMRP and
APP have evolutionarily conserved roles in regulating embryonic
and adult neurogenesis (Hayashi et al., 1994; Ohsawa et al.,
1999; Caille et al., 2004; Callan et al., 2010; Luo et al., 2010;
Demars et al., 2011; Nicolas and Hassan, 2014; Wang et al.,
2014, 2016; Faulkner et al., 2015; Halevy et al., 2015). FMRP
regulates the translation of both Ascl1 (Fahling et al., 2009) and
APP (Westmark and Malter, 2007; Lee et al., 2010). Ascl1 is
involved in the transcriptional regulation of genes associated
with all major steps of neurogenesis (Castro et al., 2011).
APP expression, trafficking, and processing are dynamically
regulated during neuronal differentiation (Bergstrom et al.,
2016; Ramaker et al., 2016). The APP metabolite amyloid-beta
upregulates expression of Ascl1 (Uchida et al., 2007) and drives
the differentiation of progenitor cells toward a neuronal lineage
(Calafiore et al., 2006). Thus, defective crosstalk among Asc1 and
APP metabolites in the absence of FMRP likely contributes to
accelerated neurogenesis in FXS. Early interventions targeted at
normalizing this signaling pathway could promote normal brain
development.
The shFmr1 mESC model developed by the Bardoni
laboratory overcomes the inherent ethical and scientific problems
associated with human FMR1 embryonic stem cells (hESC), most
of which carry the methylated and silenced full mutation and/or
are mosaic in CGG-repeat length and exhibit residual FMRP
expression. In essence, this elegant work addresses the three
main challenges of the FXS field by: (1) developing a Fmr1
knockdown stem cell model that allows study of the earliest
events of neurogenesis to support NBS and early intervention;
(2) identifying a role for APP in the kinetics of neurogenesis,
which supports the development of APP metabolites as potential
FXS biomarkers; and (3) demonstrating rescue of shFmr1 mESC
morphology with a BACE-1 inhibitor thus promoting study of
APP and secretases as therapeutic targets for FXS.
Khalfallah and colleagues contribute a vital piece to the
FXS puzzle in describing development of a mESC model
that allows study of early molecular events underlying disease
development and provides a new platform for preclinical drug
testing. Substantial data is provided validating the morphological
and molecular characteristics of the shFmr1 mESC as well
as demonstrating rescue of phenotypes by re-introduction of
FMRP or by targeting APP processing via inhibition of BACE-
1. Future experiments could examine expression of various APP
metabolites on neurogenesis, compare BACE-1 and mGluR5
inhibitors, confirm FXS signaling pathways in this early disease-
stage model, and transfect plasmids carrying varying length CGG
repeats in the human FMR1 gene to mimic the repeat expansion
aspect of the disorder.
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